Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Tóm tắt
BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional similarity assessment is a key component of demonstrating biosimilarity between a reference biologic and a proposed biosimilar. Here we report the physicochemical and functional similarity of BAT1706 and reference bevacizumab sourced from both the United States (US-bevacizumab) and the European Union (EU-bevacizumab). A large range of product attributes, including primary and higher order structure, post-translational modifications, purity, stability, and potency, were characterized for BAT1706 and EU/US-bevacizumab using sensitive state-of-the-art analytical techniques. Up to 18 lots of US- and 29 lots of EU-bevacizumab, and 10 unique drug substance lots of BAT1706, were assessed. BAT1706 was shown to have an identical amino acid sequence and an indistinguishable higher-order structure compared with EU/US-bevacizumab. BAT1706 and EU/US-bevacizumab also exhibited similar post-translational modifications, glycan profiles, and charge variants. Potency, assessed using a wide range of bioassays, was also shown to be comparable between BAT1706 and EU/US-bevacizumab, with statistical equivalence demonstrated for VEGF-A binding and neutralizing activity. Overall, this extensive comparability exercise demonstrated BAT1706 to match EU/US-bevacizumab in terms of all physicochemical and functional attributes assessed.
Tài liệu tham khảo
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim H-K, Heinonen E, Ho K, Thorpe R, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690–3. https://doi.org/10.1038/nbt.1936.
Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52. https://doi.org/10.1038/nri2747.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). European Medicines Agency. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf Accessed 3 Dec 2022.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations; Guidance for industry. US Food and Drug Administration. 2019. https://www.fda.gov/media/125484/download. Accessed 3 Dec 2022.
U.S. Department of Health and Human Services, Food and Drug Administration. Statistical approaches to evaluate analytical similarity; Guidance for industry. US Food and Drug Administration. 2017. https://www.pbwt.com/content/uploads/2018/06/UCM576786.pdf. Accessed 3 Dec 2022.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. https://doi.org/10.1038/nrd1381.
Genentech, Inc. Avastin (bevacizumab) prescribing information. Revised 2016 https://www.gene.com/download/pdf/avastin_prescribing.pdf Accessed 3 Dec 2022.
Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949–59. https://doi.org/10.1093/glycob/cwr027.
Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. https://doi.org/10.1074/jbc.M202069200.
Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–45. https://doi.org/10.1007/s10456-004-8272-2.
Flynn GC, Chen X, Liu YD, Shah B, Zhang Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol. 2010;47(11–12):2074–82. https://doi.org/10.1016/j.molimm.2010.04.006.
Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34. https://doi.org/10.1093/glycob/cwv065.
Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005;21(6):1644–52. https://doi.org/10.1021/bp050228w.
Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 1995;32(17–18):1311–8. https://doi.org/10.1016/0161-5890(95)00118-2.
Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34(12):1785–8. https://doi.org/10.1248/bpb.34.1785.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85. https://doi.org/10.1007/s10456-011-9249-6.
Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti–vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res. 2008;14(4):1239–47. https://doi.org/10.1158/1078-0432.CCR-07-1669.
U.S. Department of Health and Human Services, Food and Drug Administration. Questions and answers on biosimilar development and the BPCI act; Guidance for industry. US Food and Drug Administration. 2021. https://www.fda.gov/media/119258/download. Accessed 3 Dec 2022.
Wu X, Wynne C, Xu C, Gan Y, Wang C, Thomas BE, Yu JC, Li S, Zhang L. A global phase I clinical study comparing the safety and pharmacokinetics of proposed biosimilar BAT1706 and Bevacizumab (Avastin®) in healthy male subjects. BioDrugs. 2019;33(3):335–42. https://doi.org/10.1007/s40259-019-00352-7.
Chen L, Trukhin D, Kolesnik O, Rangel JDDG, Cil T, Li X, Cicin I, Kobziev O, Shen Y, Liu Z, et al. Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: a randomized, double-blind, phase III study. J Clin Oncol. 2022;40(Suppl 16):9041–9041. https://doi.org/10.1200/JCO.2022.40.16_suppl.9041.